Cost-Effectiveness of Vemurafenib as a First-Line Treatment in Patients with Braf V600 Mutation-Positive Unresectable or Metastatic Melanoma in Spain

Nov 1, 2015, 00:00 AM
10.1016/j.jval.2015.09.1148
https://www.valueinhealthjournal.com/article/S1098-3015(15)03224-6/fulltext
Section Title : Research Podium Presentations - Session 1 and Session 2
Section Order : 653
First Page : A453
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03224-6&doi=10.1016/j.jval.2015.09.1148
HEOR Topics :
Tags :
Regions :